-
Colorectal Cancer (CRC) Precision Medicine! Mesa East Keytruda is approved by the European Union: first-line treatment MSI-H/dMMR metastasis CRC!
Time of Update: 2021-03-04
faced adverse outcomes. this approval marks Keytruda's first gastroenteritis in Europe and makes Keytruda the first anti-PD-1/L1 therapy approved in Europe for these patients. the United States, Keytruda's single-drug first-line
-
"One brother" easy to master, pharmacy TOP20 shuffle! 3 varieties of big rise, slow-disease medicine "over the screen", is sunny "rise"
Time of Update: 2021-03-04
varieties of attovastatin calcium tablets topped the list, chlororeta tablets for the first time on the list; first break 50 billion yuan, slow-disease drugs, the original research drug "over-screen" Figure 1:2016-2020E key city physical pharmacy
-
The second round of volume procurement fire has been burned to self-cost medicine
Time of Update: 2021-03-04
In addition to Acapo sugar and solana, Adelfovesters, tadalaf and Allison Tan are all self-cost drugs, meaning that the war on volume purchases has spread above the price of medicines outside the National Health Insurance Directory.
-
China Resources Pharmaceutical Holdings indirectly holds a 30% stake in Jiang Traditional Chinese Medicine
Time of Update: 2021-03-04
Pharmaceutical Holdings' indirect ownership of Jiangzhong Pharmaceuticals through Jiangzhong Group will exceed 30% of Jiangzhong Pharmaceutical's already issued shares, triggering a full offer obligation. It is understood that the decision-making
-
New medicine for rare lung disease! Roche Esbriet (pyridone) is reviewed by the FDA as a priority
Time of Update: 2021-03-04
phase II clinical trial data show that Esbriet slowed the progression of the disease in UIDD patients at 24 weeks of treatment compared to a placebo.
-
Innovative medicine blows! Hengrui's half-year revenue of 10 billion Chinese biopharmaceuticals 12.5 billion
Time of Update: 2021-03-04
and treatment options. At present, Karelli pearl single anti-pricing specifications of 200mg per bottle in 198,000 yuan, compared with the Junshi biological, Thyda biological and other peer competition is undoubtedly higher than a ladder. How to compete
-
Dongguan public hospitals to propose or reduce the price of medicines and medical supplies
Time of Update: 2021-03-04
Dongguan city public medical institutions to take a full increase in consumables! The "Dongguan City 2018 Public Medical Service Price Reform Program (Draft for Comments)" (hereinafter referred to as the "Reform Plan"), drafted by the Dongguan
-
Pre-loss of more than 2.2 billion yuan! People's fu medicine 3 billion goodwill "thunderstorm" landed at once
Time of Update: 2021-03-04
billion yuan in 2017, and the net profit of the parent company increased from 216 million yuan in 2010 to 2.069 billion yuan in 2017, nearly 10 times in seven years. Founded in 1993 and listed on the Shanghai Stock Exchange in 1997 (600079
-
"Sky-price ticket" limited effect of life-saving drugs cheap medicine cut off the solution
Time of Update: 2021-03-03
for treating acute lymphoblastic leukemia in children, especially during the maintenance period of more than a year, if the drug is stopped, it will greatly affect the long-term survival effect of children. Because the profit is not high
-
Severe muscle weakness (MG) new drug! The National Drug Administration grants and platinum medicine
Time of Update: 2021-03-03
binding to each other and accelerates the removal of IgG in the body, thus effectively treating autoimmune diseases mediated by pathogenic IgG. available evidence suggests that lower IgG levels in patients with severe muscle weakness (MG
-
"Gene-edited baby" case: scientific research under the guise of illegal practice of medicine
Time of Update: 2021-03-03
; " three defendants in the absence of medical qualifications to carry out medical acts, in violation of the state prohibition provisions, the illegal use of immature technology on human beings, has been a serious case, in line with the composition
-
The core variety of Yasheng Medicine, HQP1351, was qualified as an FDA orphan drug
Time of Update: 2021-03-03
HQP1351, China's first third-generation BCR-ABL targeted drug-resistant CML treatment, is currently in the critical Phase II clinical trial phase and plans to submit a new drug listing application (NDA) this year.
-
Promote the tilt of medical insurance policy towards Chinese medicine
Time of Update: 2021-03-01
Medical Security to Support the Development of Traditional Chinese Medicine", referring to the need to make full use of the national medical insurance drug catalogue and the dynamic adjustment mechanism of the national basic drug catalogue, to support
-
Beijing intends to integrate Chinese medicine into the public health system
Time of Update: 2021-02-28
"Beijing Regulations on Traditional Chinese Medicine (Draft for Public Comment)" drafted by the Beijing Municipal Health and Health Commission and the Municipal Chinese Medicine Bureau in cooperation with relevant departments, has
-
Liao let go of the Chinese medicine formula particles in the national blank area is not much left
Time of Update: 2021-02-28
On June 19th, Liaoning Provincial Health and Planning Commission, Industry and Information Technology Commission and Food and Drug Administration jointly issued the Notice on the Declaration of Special Projects for Research on Chinese Medicine
-
Yunnan white medicine and other products to raise prices OTC ushered in a sustained wave of price increases?
Time of Update: 2021-02-28
an interview with Securities Daily, a Chinese pharmaceutical executive said that since the state liberalized the market pricing power of OTC drugs, the company's low-cost product prices gradually increased.
-
Chinese medicine injection limit companies under pressure China Resources 39 and other products sales decline
Time of Update: 2021-02-28
The pressure of national medical insurance fee control continues, and medical institutions increase the monitoring of auxiliary drug use, which has an impact on the market sales of Chinese medicine injections. recently, China Resources 39
-
China Resources Medicine "eats" stomach-churning tablets
Time of Update: 2021-02-27
"Daily Economic News" reporter learned that after the completion of the capital increase, China Resources Pharmaceutical Holdings will hold a 51% stake in Jiang zhong group, thereby indirectly controlling jiang chinese medicine has issued shares of 43.03 percent.
-
5 billion yuan "white medicine" market pattern changes Hengrui 19K into the big
Time of Update: 2021-02-27
, while sales of Neulasta, a long-acting dosage form, have risen rapidly since their launch, peaking at $4.715 billion in 2015, making it a well-deserved heavyweight star product. In the same year, short-acting dosage forms achieved sales of $1,049 million
-
Huaren Pharmaceuticals' proposed acquisition of Korean medicine and cosmetics marriage will have a "spark"?
Time of Update: 2021-02-27
On the evening of October 17th, Huaren Pharmaceuticals, which had earlier announced that it would acquire a well-known cosmetics company in China, finally lifted the mystery of the target, which was acquired by Han post cosmetics Co., Ltd.
